Warning letters, 483s, Recalls, Import Alerts, Audit observations
In November 2025, the USFDA issued a Warning Letter to Bangalore-based Cdymax India following an
Novo Nordisk’s Bloomington plant (FEI 3005949964, Catalent Indiana LLC) is classified OAI by USFDA in
The USFDA issued a Warning letter to Hikal’s API facility in Jigani, Bangalore, India. The
In September 2025, the USFDA classified Sun Pharmaceutical Industries Ltd.’s Halol facility as OAI (Official
The USFDA issued a Warning letter to Amneal Pharmaceuticals following critical deviations observed during an
Novo Nordisk owned Catalent Indiana sterile products formulation facility was inspected by USFDA in June
The U.S. FDA issued a warning letter to International Laboratories Corp. (FEI 3006403166) following CGMP
Piramal Pharma’s API unit at Navi Mumbai (FEI 3008763768) was issued USFDA Form 483 with
Indoco Remedies’ Goa Plant (FEI 3005124189) received a warning letter from the FDA following critical
Authored by: Venkiteswaran.T.K, Subrangshu Chourdhary, Srinivas Churya Jubilant Generics Roorkee facility was inspected in January
